Organism/ Antimicrobial
|
2004–2016
|
2013–2016
|
---|
MIC90 (mg/L)
|
MIC Range (mg/L)
|
% S
|
% R
|
MIC90 (mg/L)
|
MIC Range (mg/L)
|
% S
|
% R
|
---|
Enterobacter spp.
|
N = 3424
|
N = 924
|
Amikacin
|
4
|
≤0.5 to ≥128
|
96.9
|
1.1
|
4
|
≤0.5 to ≥128
|
98.4
|
0.8
|
Cefepimea
|
16
|
≤0.5 to ≥64
|
69.5
|
15.8
|
32
|
≤0.5 to ≥64
|
67.1
|
19.8
|
Ceftriaxone
|
64
|
≤0.06 to ≥128
|
50.9
|
45.6
|
64
|
≤0.06 to 64
|
49.1
|
47.3
|
Levofloxacinc
|
≤16
|
≤0.008 to ≥16
|
71.5
|
25.0
|
8
|
≤0.008 to ≥16
|
75.8
|
19.7
|
Meropenem (N = 3113)b
|
0.25
|
≤0.06 to ≥32
|
99.2
|
0.3
|
0.25
|
≤0.06 to ≥32
|
99.4
|
0.2
|
Minocycline
|
16
|
≤0.5 to ≥32
|
–
|
–
|
8
|
≤0.5 to ≥32
|
–
|
–
|
Pip-tazc
|
128
|
≤0.06 to ≥256
|
60.7
|
30.5
|
128
|
≤0.06 to ≥256
|
64.7
|
25.6
|
Tigecycline
|
2
|
0.06 to 16
|
86.3
|
5.2
|
2
|
0.06 to 16
|
89.5
|
3.5
|
E. coli
|
N = 3527
|
N = 965
|
Amikacin
|
4
|
≤0.5 to ≥128
|
98.1
|
0.5
|
4
|
≤0.5 to ≥128
|
98.4
|
0.2
|
Amox-clav
|
32
|
0.25 to ≥64
|
72.1
|
27.9
|
16
|
0.5 to ≥64
|
75.1
|
24.9
|
Ampicillin
|
≥64
|
≤0.5 to ≥64
|
37.9
|
62.1
|
≥64
|
≤0.5 to ≥64
|
38.5
|
61.5
|
Cefepimea
|
8
|
≤0.5 to ≥64
|
82.5
|
12.4
|
16
|
≤0.5 to ≥64
|
80.7
|
13.8
|
Ceftriaxonea
|
64
|
≤0.06 to ≥128
|
82.6
|
16.8
|
64
|
≤0.06 to 64
|
81.3
|
18.4
|
Levofloxacin
|
≥16
|
≤0.008 to ≥16
|
78.5
|
20.2
|
8
|
≤0.008 to ≥16
|
79.6
|
19.4
|
Meropenem (N = 3203)b
|
≤0.06
|
≤0.06 to 8
|
99.9
|
0.0
|
≤0.06
|
≤0.06 to 8
|
99.9
|
0.0
|
Minocycline
|
8
|
≤0.5 to ≥32
|
–
|
–
|
8
|
≤0.5 to ≥32
|
–
|
–
|
Pip-taz
|
16
|
≤0.06 to ≥256
|
89.6
|
7.2
|
8
|
≤0.06 to ≥256
|
91.6
|
6.2
|
Tigecycline
|
0.5
|
≤0.008 to 16
|
99.4
|
0.1
|
0.25
|
0.03 to 16
|
99.5
|
0.1
|
E. coli, ESBL
|
N = 489
|
N = 156
|
Amikacin
|
8
|
≤0.5 to ≥128
|
92.6
|
2.2
|
8
|
1 to ≥128
|
95.5
|
0.6
|
Amox-clavc
|
32
|
2 to ≥64
|
45.8
|
54.2
|
16
|
2 to ≥64
|
59.0
|
41.0
|
Ampicillin
|
≥64
|
32 to ≥64
|
0.0
|
100
|
≥64
|
64 to ≥64
|
0.0
|
100
|
Cefepime
|
≥64
|
≤0.5 to ≥64
|
3.9
|
78.3
|
≥64
|
1 to ≥64
|
3.2
|
79.5
|
Ceftriaxone
|
≥128
|
2 to ≥128
|
0.0
|
99.2
|
64
|
4 to 64
|
0.0
|
100
|
Levofloxacin
|
≥16
|
≤0.008 to ≥16
|
37.8
|
59.7
|
≥16
|
0.015 to ≥16
|
42.3
|
55.1
|
Meropenem (N = 472)b
|
≤0.06
|
≤0.06 to 2
|
100
|
0.0
|
≤0.06
|
≤0.06 to 1
|
100
|
0.0
|
Minocycline
|
16
|
≤0.5 to ≥32
|
–
|
–
|
16
|
≤0.5 to ≥32
|
–
|
–
|
Pip-tazc
|
32
|
0.25 to ≥256
|
78.3
|
12.7
|
16
|
0.25 to ≥256
|
88.5
|
3.8
|
Tigecycline
|
0.5
|
0.03 to 2
|
99.2
|
0.0
|
0.25
|
0.03 to 2
|
99.4
|
0.0
|
H. influenzae
|
N = 1786
|
N = 494
|
Amikacin
|
8
|
≤0.5 to 64
|
–
|
–
|
8
|
≤0.5 to 16
|
–
|
–
|
Amox-clav
|
1
|
≤0.12 to 16
|
99.2
|
0.8
|
1
|
≤0.12 to 4
|
99.0
|
1.0
|
Ampicillin
|
32
|
≤0.5 to ≥64
|
75.4
|
24.6
|
32
|
≤0.5 to ≥64
|
74.1
|
25.9
|
Cefepime
|
≤0.5
|
≤0.5 to 2
|
–
|
–
|
≤0.5
|
≤0.5 to 2
|
–
|
–
|
Ceftriaxone
|
≤0.06
|
≤0.06 to 4
|
98.6
|
1.4
|
≤0.06
|
≤0.06 to 2
|
99.4
|
0.4
|
Levofloxacin
|
0.015
|
≤0.008 to 8
|
98.4
|
1.6
|
0.015
|
≤0.008 to 8
|
98.6
|
1.4
|
Meropenem (N = 1629)b
|
0.12
|
≤0.06 to 0.5
|
100
|
0.0
|
0.12
|
≤0.06 to 0.5
|
100
|
0.0
|
Minocycline
|
1
|
≤0.5 to 16
|
91.8
|
1.6
|
1
|
≤0.5 to 4
|
93.1
|
0.8
|
Pip-taz
|
≤0.06
|
≤0.06 to 0.5
|
–
|
–
|
≤0.06
|
≤0.06 to 0.5
|
–
|
–
|
Tigecycline
|
0.25
|
≤0.008 to 4
|
–
|
–
|
0.25
|
≤0.008 to 0.25
|
–
|
–
|
H. influenzae, BL Positive
|
N = 410
|
N = 122
|
Amikacin
|
8
|
≤0.5 to 32
|
–
|
–
|
8
|
≤0.5 to 16
|
–
|
–
|
Amox-clav
|
2
|
≤0.12 to 16
|
97.3
|
2.7
|
2
|
≤0.12 to 4
|
95.9
|
4.1
|
Ampicillin
|
≥64
|
≤0.5 to ≥64
|
0.5
|
99.5
|
≥64
|
≤0.5 to ≥64
|
0.8
|
99.2
|
Cefepime
|
≤0.5
|
≤0.5 to 2
|
–
|
–
|
≤0.5
|
≤0.5 to 2
|
–
|
–
|
Ceftriaxone
|
≤0.06
|
≤0.06 to 4
|
97.8
|
2.2
|
≤0.06
|
≤0.06 to 2
|
99.2
|
0.8
|
Levofloxacin
|
0.03
|
≤0.008 to 1
|
97.8
|
2.2
|
0.015
|
≤0.008 to 0.5
|
97.5
|
2.5
|
Meropenem (N = 378)b
|
0.12
|
≤0.06 to 0.5
|
100
|
0.0
|
0.12
|
≤0.06 to 0.5
|
100
|
0.0
|
Minocycline
|
1
|
≤0.5 to 16
|
93.2
|
0.5
|
1
|
≤0.5 to 2
|
93.4
|
0.0
|
Pip-taz
|
≤0.06
|
≤0.06 to 0.5
|
–
|
–
|
≤0.06
|
≤0.06 to 0.5
|
–
|
–
|
Tigecycline
|
0.25
|
≤0.008 to 0.5
|
–
|
–
|
0.25
|
≤0.008 to 0.25
|
–
|
–
|
K. oxytoca
|
N = 975
|
N = 225
|
Amikacin
|
4
|
≤0.5 to ≥128
|
98.9
|
0.4
|
4
|
≤0.5 to 16
|
99.1
|
0.0
|
Amox-clav
|
32
|
0.25 to ≥64
|
79.8
|
20.2
|
16
|
0.25 to ≥64
|
82.2
|
17.8
|
Cefepime
|
2
|
≤0.5 to ≥64
|
88.4
|
3.9
|
2
|
≤0.5 to ≥64
|
88.4
|
4.9
|
Ceftriaxone
|
8
|
≤0.06 to ≥128
|
83.2
|
14.5
|
4
|
≤0.06 to 64
|
85.8
|
12.0
|
Levofloxacin
|
1
|
≤0.008 to ≥16
|
89.5
|
8.4
|
0.25
|
0.015 to ≥16
|
94.2
|
4.4
|
Meropenem (N = 872)b
|
≤0.06
|
≤0.06 to ≥32
|
99.8
|
0.1
|
≤0.06
|
≤0.06 to 1
|
100
|
0.0
|
Minocycline
|
4
|
≤0.5 to ≥32
|
–
|
–
|
2
|
≤0.5 to 16
|
–
|
–
|
Pip-taz
|
≥256
|
≤0.06 to ≥256
|
84.0
|
15.1
|
64
|
0.25 to ≥256
|
87.6
|
11.6
|
Tigecycline
|
1
|
0.015 to 8
|
95.8
|
1.0
|
0.5
|
0.12 to 4
|
96.9
|
0.9
|
K. pneumoniae
|
N = 2398
|
N = 690
|
Amikacin
|
4
|
≤0.5 to ≥128
|
96.5
|
1.5
|
4
|
≤0.5 to ≥128
|
96.8
|
1.7
|
Amox-clava
|
32
|
0.5 to ≥64
|
68.6
|
31.4
|
32
|
1 to ≥64
|
61.4
|
38.6
|
Cefepimea
|
≥64
|
≤0.5 to ≥64
|
72.1
|
23.4
|
≥64
|
≤0.5 to ≥64
|
59.9
|
35.5
|
Ceftriaxonea
|
64
|
≤0.06 to ≥128
|
70.3
|
28.7
|
64
|
≤0.06 to 64
|
58.4
|
41.4
|
Levofloxacina
|
8
|
≤0.008 to ≥16
|
76.1
|
20.0
|
8
|
0.015 to ≥16
|
72.3
|
23.2
|
Meropenema (N = 2186)b
|
0.12
|
≤0.06 to ≥32
|
99.4
|
0.4
|
0.12
|
≤0.06 to ≥32
|
98.8
|
1.0
|
Minocycline
|
16
|
≤0.5 to ≥32
|
–
|
–
|
16
|
≤0.5 to ≥32
|
–
|
–
|
Pip-taz
|
64
|
0.12 to ≥256
|
81.9
|
13.1
|
32
|
0.12 to≥256
|
84.1
|
10.3
|
Tigecyclinea
|
2
|
0.06 to 16
|
87.4
|
5.0
|
2
|
0.06 to 8
|
86.2
|
7.0
|
K. pneumoniae, ESBL
|
N = 622
|
N = 265
|
Amikacin
|
8
|
≤0.5 to ≥128
|
90.0
|
4.2
|
8
|
≤0.5 to ≥128
|
94.7
|
3.8
|
Amox-clav
|
32
|
1 to ≥64
|
19.0
|
81.0
|
32
|
1 to ≥64
|
20.8
|
79.2
|
Cefepimea
|
≥64
|
≤0.5 to ≥64
|
5.0
|
85.0
|
≥64
|
≤0.5 to ≥64
|
3.8
|
86.8
|
Ceftriaxone
|
≥128
|
≤0.06 to ≥128
|
1.3
|
98.4
|
64
|
≤0.06 to 64
|
1.1
|
98.9
|
Levofloxacinc
|
≥16
|
0.03 to ≥16
|
30.2
|
61.1
|
≥16
|
0.03 to ≥16
|
38.9
|
50.9
|
Meropenem (N = 603)b
|
0.12
|
≤0.06 to ≥32
|
99.0
|
0.3
|
0.12
|
≤0.06 to 16
|
99.2
|
0.4
|
Minocycline
|
≥32
|
≤0.5 to ≥32
|
–
|
–
|
≥32
|
≤0.5 to ≥32
|
–
|
–
|
Pip-tazc
|
≥256
|
0.25 to ≥256
|
54.0
|
32.8
|
128
|
0.25 to ≥256
|
68.7
|
18.5
|
Tigecycline
|
2
|
0.12 to 8
|
79.4
|
7.2
|
2
|
0.12 to 8
|
80.0
|
7.9
|
S. marcescens
|
N = 1345
|
N = 360
|
Amikacin
|
4
|
≤0.5 to ≥128
|
97.3
|
1.1
|
4
|
≤0.5 to 64
|
98.3
|
0.6
|
Cefepime
|
≤0.5
|
≤0.5 to ≥64
|
94.5
|
2.2
|
≤0.5
|
≤0.5 to ≥32
|
94.7
|
1.9
|
Ceftriaxone
|
8
|
≤0.06 to ≥128
|
82.2
|
13.8
|
2
|
≤0.06 to 64
|
86.9
|
8.9
|
Levofloxacinc
|
2
|
≤0.008 to ≥16
|
84.2
|
10.6
|
1
|
≤0.008 to ≥16
|
89.4
|
5.6
|
Meropenem (N = 1227)b
|
0.12
|
≤0.06 to ≥32
|
99.1
|
0.1
|
0.12
|
≤0.06 to 2
|
100
|
0.0
|
Minocycline
|
8
|
≤0.5 to ≥32
|
–
|
–
|
4
|
≤0.5 to ≥32
|
–
|
–
|
Pip-taz
|
16
|
≤0.06 to ≥256
|
89.9
|
6.2
|
8
|
≤0.06 to 128
|
93.9
|
3.3
|
Tigecycline
|
2
|
0.015 to 8
|
80.7
|
2.6
|
2
|
0.03 to 4
|
80.3
|
1.1
|
A. baumannii
|
N = 1496
|
N = 270
|
Amikacin
|
≥128
|
≤0.5 to ≥128
|
74.9
|
19.9
|
≥128
|
1 to ≥128
|
73.7
|
20.4
|
Cefepime
|
32
|
≤0.5 to ≥64
|
–
|
–
|
≥64
|
≤0.5 to ≥64
|
–
|
–
|
Ceftazidime (N = 1488)
|
≥64
|
≤1 to ≥64
|
–
|
–
|
32
|
≤1 to 32
|
–
|
–
|
Ceftriaxone
|
≥128
|
≤0.06 to ≥128
|
–
|
–
|
64
|
2 to 64
|
–
|
–
|
Levofloxacin
|
≥16
|
≤0.008 to ≥16
|
54.5
|
43.2
|
≥16
|
≤0.008 to ≥16
|
56.7
|
42.6
|
Meropenema (N = 1326)b
|
≥32
|
≤0.06 to ≥32
|
81.0
|
11.8
|
≥32
|
0.12 to ≥32
|
74.1
|
20
|
Minocycline
|
8
|
≤0.5 to ≥32
|
–
|
–
|
8
|
≤0.5 to ≥32
|
–
|
–
|
Pip-taz
|
≥256
|
≤0.06 to ≥256
|
–
|
–
|
≥256
|
≤0.06 to ≥256
|
–
|
–
|
Tigecycline
|
1
|
≤0.008 to 8
|
–
|
–
|
1
|
0.03 to 2
|
–
|
–
|
A. baumannii MDR
|
N = 93
|
N = 35
|
Amikacin
|
≥128
|
32 to ≥128
|
0.0
|
100
|
≥128
|
32 to ≥128
|
0.0
|
100
|
Cefepime
|
≥64
|
8 to ≥64
|
–
|
–
|
≥64
|
8 to ≥64
|
–
|
–
|
Ceftazidime (N = 92)
|
≥64
|
≤1 to ≥64
|
–
|
–
|
32
|
2 to 32
|
–
|
–
|
Ceftriaxone
|
≥128
|
64 to ≥128
|
–
|
–
|
64
|
64 to 64
|
–
|
–
|
Levofloxacin
|
≥16
|
2 to ≥16
|
0.0
|
100
|
≥16
|
2 to ≥16
|
0.0
|
100
|
Meropenem (N = 92)b
|
≥32
|
16 to ≥32
|
0.0
|
100
|
≥32
|
16 to ≥32
|
0.0
|
100
|
Minocycline
|
16
|
≤0.5 to ≥32
|
–
|
–
|
16
|
≤0.5 to ≥32
|
–
|
–
|
Pip-taz
|
≥256
|
≤0.06 to ≥256
|
–
|
–
|
≥256
|
64 to ≥256
|
–
|
–
|
Tigecycline
|
4
|
0.12 to 4
|
–
|
–
|
2
|
0.25 to 2
|
–
|
–
|
P. aeruginosa
|
N = 2734
|
N = 738
|
Amikacin
|
16
|
≤0.5 to ≥128
|
88.5
|
6.9
|
8
|
≤0.5 to ≥128
|
91.1
|
5.1
|
Cefepime
|
32
|
≤0.5 to ≥64
|
77.8
|
22.2
|
16
|
≤0.5 to ≥64
|
79.8
|
20.2
|
Ceftazidime (N = 2730)
|
32
|
≤1 to ≥64
|
77.2
|
22.8
|
32
|
≤1 to 32
|
80.2
|
19.8
|
Levofloxacinc
|
≥16
|
≤0.008 to ≥16
|
60.6
|
39.4
|
≥16
|
0.015 to ≥16
|
65.7
|
34.3
|
Meropenem (N = 2474)
|
8
|
≤0.06 to ≥32
|
74.6
|
8.7
|
16
|
≤0.06 to ≥32
|
75.2
|
10.0
|
Pip-tazc
|
128
|
≤0.06 to ≥256
|
74.4
|
25.6
|
128
|
≤0.06 to ≥256
|
78.7
|
21.3
|
Tigecycline
|
16
|
≤0.008 to ≥32
|
–
|
–
|
16
|
0.12 to 16
|
–
|
–
|
P. aeruginosa MDR
|
N = 271
|
N = 68
|
Amikacin
|
≥128
|
1 to ≥128
|
31.4
|
58.3
|
≥128
|
2 to ≥128
|
38.2
|
50.0
|
Cefepime
|
≥64
|
2 to ≥64
|
14.0
|
86.0
|
≥64
|
4 to ≥64
|
8.8
|
91.2
|
Ceftazidime
|
≥64
|
2 to ≥64
|
21.4
|
78.6
|
32
|
4 to 32
|
23.5
|
76.5
|
Levofloxacin
|
≥16
|
0.5 to ≥16
|
1.5
|
98.5
|
≥16
|
2 to ≥16
|
0.0
|
100
|
Meropenema (N = 258)b
|
≥32
|
≤0.06 to ≥32
|
17.8
|
66.7
|
≥32
|
0.25 to ≥32
|
11.8
|
82.4
|
Pip-tazc
|
≥256
|
0.5 to ≥256
|
14.0
|
86.0
|
≥256
|
1 to ≥256
|
20.6
|
79.4
|
Tigecycline
|
≥32
|
1 to ≥32
|
–
|
–
|
16
|
2 to 16
|
–
|
–
|
- – indicates no susceptibility breakpoints are available for this agent
- a indicates statistically significant decrease in susceptibility (p < 0.01) from 2004 to 2016
- b Meropenem was introduced to the testing panel in 2006, replacing imipenem; N values of activity against organisms collected from 2006 to 2016 are given
- c indicates statistically significant increase in susceptibility (p < 0.01) from 2004 to 2016
- Amox-clav, amoxicillin-clavulanic acid, BL, β-lactamase, ESBL, extended-spectrum β-lactamase, MDR, multidrug-resistant, MIC, minimum inhibitory concentration, MIC90, minimum inhibitory concentration required to inhibit growth of 90% of isolates (mg/L), Pip-taz, piperacillin-tazobactam, R, resistant, S, susceptible